Do we have any evidence that what matters is the change in O2 rather than the time spent in hypoxia?
If that were the case, we would find many papers showing the benefits of intermittent hyperoxic therapy. But I couldn’t find a single one. On the other hand, there are many papers on the benefits of intermittent hypoxic therapy or combined hypoxia–hyperoxia.
Also, this paper suggests that it’s just that at 30%, the body thinks it is in hypoxia: Oxygen Variations—Insights into Hypoxia, Hyperoxia and Hyperbaric Hyperoxia—Is the Dose the Clue? 2023
Fratantonio et al. [14] described the activation time trend of oxygen-sensitive transcription factors in human peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects after one hour of exposure to mild (MH), high (HH), and very high (VHH) hyperoxia, corresponding to 30%, 100%, and 140% O2, respectively. They confirmed that MH is perceived as a hypoxic stress, characterized by the activation of HIF-1 α and nuclear factor (erythroid-derived 2)-like 2 (NRF2), but not of the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-kB). Conversely, HH is associated with a progressive increase in oxidative stress leading to NRF2 and NF-kB activation, accompanied by the synthesis of glutathione (GSH). After VHH, HIF-1 α activation is totally absent and oxidative stress response, accompanied by NF-kB activation, is prevalent. Intracellular GSH and Matrix metallopeptidase 9 (MMP-9) plasma levels parallel the transcription factors’ activation patterns and remain elevated throughout the observation time (24 h). This confirms that, in vivo, the return to normoxia after MH is sensed as a hypoxic trigger characterized by HIF-1 α activation. On the contrary, HH and VHH induce a shift toward an oxidative stress response, characterized by NRF2 and NF-kB activation in the first 24 h post-exposure.
If I’m correct hen what matters is the time in hypoxia, not the degree of change: HIF1α/SLC7A11 signaling attenuates 6-hydroxydopamine-induced ferroptosis in animal and cell models of Parkinson’s disease 2025
Hypoxia-inducible factor-1α (HIF1α) is a transcription factor consisting of α and β subunits. In the presence of normal oxygen levels (normoxic state), HIF1α undergoes hydroxylation by prolinehydroxylase (PHD), leading to its degradation by the Von Hippel-Lindau (VHL) complex. However, in hypoxic conditions, this degradation process is inhibited, allowing HIF1α to accumulate and form a complex with HIF1β. Subsequently, HIF1α translocates from the cytoplasma to the nucleus,where it regulates the transcription of downstream genes by binding to the hypoxia response elements (HREs).9 Yang et al showed that HIF1α, but not HIF2α, played crucial roles in ferroptosis resistance of cancer cells under hypoxia via upregulation of the glutamate transporter SLC1A1.
(Also interesting from this paper: “Our findings shown a significant decrease in HIF1α expression in both animal and cell models of PD induced by 6-OHDA. Moreover, upregulation of HIF1α promoted ferroptosis, while downregulation of HIF1α inhibited this process. These findings indicate that HIF1α has diverse roles in diseases associated with ferroptosis.”)
I also trust the “Lindiness” of hypoxia: going in altitude for a retreat has been considered healthy for a long time. See also: Acute and cumulative effects of hypoxia exposure in people with Parkinson’s disease: A scoping review and evidence map 2024